[Clinical and therapeutic aspects of prolactinoma in men].
Macroprolactinomas predominate in males in comparison to microprolactinomas, with greater trend to invasiveness than in females. The clinical treatment has been the first option to prolactinomas, in both macro and microadenomas, irrespective the sex. We compared clinical presentation, prolactin levels, neuroradiologic invasiveness and prolactinemia response of 23 men with prolactinomas subjected to clinical therapy (group 1) with 19 who went also through surgical and/or radiotherapeutic treatment (group 2). The statistical analysis was done by the tests of chi-square or exact of Fisher, in order to compare proportions, and by t of Student or Mann-Whitney, in order to compare means. The level of significance adopted was 5% (p<0.05). The two groups were similar regarding age (p=0.23), period between start of the first symptom and diagnosis (p=0.82), prolactin levels before treatment (p=0.41) and invasive macroadenomas proportion (p=0.096). There was significantly greater percentage of headache (p=0.009) and visual deficit (p=0.025) in group 2, as well as the drug usage (p=0.007) and observation (p=0.0005) periods were superior in this group. The variations of prolactin levels before and after therapy (p=0.49) as well as the percentage of prolactin normalization (p=0.20) did not show any significant difference when comparing the two groups. We conclude, emphasizing the relevance of precocious prolactinoma diagnostic in men, because of the demonstrated morbidity. We strengthen the use of dopamine agonist as the first therapeutic option irrespective the adenoma size.
Braucks
Gisele Rieffel
GR
Faculdade de Medicina, Universidade Federal do Rio de Janeiro, RJ, Brasil. girb@gbl.com.br
Naliato
Erika Cesar de Oliveira
EC
Tabet
Ana Lúcia Osorio
AL
Gadelha
Monica Roberto
MR
Violante
Alice Helena Dutra
AH
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D015415:Biomarkers; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D016009:Chi-Square Distribution; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010911:Pituitary Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011388:Prolactin / Q000097:blood*; D015175:Prolactinoma / Q000097:blood / Q000473:pathology / Q000628:therapy*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D015415:Biomarkers; D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin; D000077465:Cabergoline